Genzyme GENZ

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Impax launches generic Renvela

      Headlines

      Wed, 16 Apr 2014

      Pharamaeuticals division launches its generic version of Genzyme 's ( SNY +0.2% ) Renvela (sevelamer carbonate ..... specific allotment of bottles granted under a license from Genzyme . Impax's aNDA for the product is currently under regulatory

    2. New Morningstar Analyst Report for Biomarin Pharmaceutical, Inc.

      Stock Reports

      Fri, 11 Apr 2014

      of BioMarin's expertise. Viral contamination forced Genzyme (now Sanofi) to halt manufacturing of its enzyme replacement ..... disease therapies, and three products drive its sales. Genzyme (now part of Sanofi) markets Aldurazyme through its joint

    3. Even simple pregnancy tests can run into problems

      Headlines

      Tue, 8 Apr 2014

      interpreted pregnancy tests have been used by women and clinicians alike for decades. All hospitals offer them. Two tests, Genzyme 's ( SNY ) OSOM and Cen-Med's Elite were so inhibited that they pose an unacceptable risk of false negatives. The

    4. Genzyme to resubmit Lemtrada application

      Headlines

      Mon, 7 Apr 2014

      Sanofi's ( SNY ) subisidiary plans to resubmit its sBLA for Lemtrada this quarter. It believes that it has addressed all the issues the FDA raised in its December 27 CRL . It will not pursue its previously-announced appeal of the FDA's decision. ( GCVRZ ) 1 comment!

    5. New Morningstar Analyst Report for Sanofi

      Stock Reports

      Fri, 14 Mar 2014

      the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision

    6. PJP PowerShares Dynamic Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Sun, 24 Nov 2013

      Industries' TEVA acquisition of German generic drugmaker Ratiopharm Group International, Sanofi's SNY acquisition of Genzyme , Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain drugmaker King Pharmaceuticals.

    7. ClearBridge Fund Prepared for Extended Rally

      Video Reports

      Fri, 11 Oct 2013

      continues. I think there is going to be a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase

      Genzyme found at 3:20

      a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase growth and do
    8. Invest With These Exemplary Management Teams

      Headlines

      Sun, 26 May 2013

      the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision

    9. Sanofi's 4Q and 2013 Guidance Match Our Projections but Fall Short of Consensus Expectations

      Commentary

      Thu, 7 Feb 2013

      quarterly results. The company's updated guidance on an improving pipeline along with steady growth from emerging markets, Genzyme products, consumer health, vaccines, and diabetes drugs increases our conviction behind our wide moat rating for the

    10. Sanofi Posts Solid 3Q Supported by Cost-Containment Efforts, but No Change to Valuation

      Commentary

      Thu, 25 Oct 2012

      growth continued to perform well, with particular strength from diabetes drug Lantus, which was up 18% year over year. Genzyme products and emerging markets also continued to post steady gains. However, generic competition to cardiovascular drug

    « Prev12345Next »
    Content Partners